Literature DB >> 28250008

Historical Controls?

Paul S Gaynon1.   

Abstract

Mesh:

Year:  2017        PMID: 28250008      PMCID: PMC5394945          DOI: 10.3324/haematol.2016.159707

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  The role of nonrandomized trials in the evaluation of oncology drugs.

Authors:  R Simon; G M Blumenthal; M L Rothenberg; J Sommer; S A Roberts; D K Armstrong; L M LaVange; R Pazdur
Journal:  Clin Pharmacol Ther       Date:  2015-04-07       Impact factor: 6.875

2.  International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.

Authors:  Nicola Gökbuget; Hervè Dombret; Jose-Maria Ribera; Adele K Fielding; Anjali Advani; Renato Bassan; Victoria Chia; Michael Doubek; Sebastian Giebel; Dieter Hoelzer; Norbert Ifrah; Aaron Katz; Michael Kelsh; Giovanni Martinelli; Mireia Morgades; Susan O'Brien; Jacob M Rowe; Julia Stieglmaier; Martha Wadleigh; Hagop Kantarjian
Journal:  Haematologica       Date:  2016-09-01       Impact factor: 9.941

3.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Authors:  Max S Topp; Nicola Gökbuget; Anthony S Stein; Gerhard Zugmaier; Susan O'Brien; Ralf C Bargou; Hervé Dombret; Adele K Fielding; Leonard Heffner; Richard A Larson; Svenja Neumann; Robin Foà; Mark Litzow; Josep-Maria Ribera; Alessandro Rambaldi; Gary Schiller; Monika Brüggemann; Heinz A Horst; Chris Holland; Catherine Jia; Tapan Maniar; Birgit Huber; Dirk Nagorsen; Stephen J Forman; Hagop M Kantarjian
Journal:  Lancet Oncol       Date:  2014-12-16       Impact factor: 41.316

Review 4.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

5.  Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.

Authors:  Richard H Ko; Lingyun Ji; Phillip Barnette; Bruce Bostrom; Raymond Hutchinson; Elizabeth Raetz; Nita L Seibel; Clare J Twist; Elena Eckroth; Richard Sposto; Paul S Gaynon; Mignon L Loh
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544

6.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Authors:  Hagop M Kantarjian; Daniel J DeAngelo; Matthias Stelljes; Giovanni Martinelli; Michaela Liedtke; Wendy Stock; Nicola Gökbuget; Susan O'Brien; Kongming Wang; Tao Wang; M Luisa Paccagnella; Barbara Sleight; Erik Vandendries; Anjali S Advani
Journal:  N Engl J Med       Date:  2016-06-12       Impact factor: 91.245

7.  Evaluating glioma therapies: modeling treatments and predicting outcomes.

Authors:  S Kirby; M Brothers; W Irish; R Florell; D Macdonald; C Schold; G Cairncross
Journal:  J Natl Cancer Inst       Date:  1995-12-20       Impact factor: 13.506

8.  Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

Authors:  N Gökbuget; M Kelsh; V Chia; A Advani; R Bassan; H Dombret; M Doubek; A K Fielding; S Giebel; V Haddad; D Hoelzer; C Holland; N Ifrah; A Katz; T Maniar; G Martinelli; M Morgades; S O'Brien; J-M Ribera; J M Rowe; A Stein; M Topp; M Wadleigh; H Kantarjian
Journal:  Blood Cancer J       Date:  2016-09-23       Impact factor: 11.037

Review 9.  Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib.

Authors:  P Selaru; Y Tang; B Huang; A Polli; K D Wilner; E Donnelly; D P Cohen
Journal:  Clin Transl Sci       Date:  2016-03-01       Impact factor: 4.689

  9 in total
  1 in total

1.  Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group.

Authors:  Caitlin W Elgarten; Andrew C Wood; Yimei Li; Todd A Alonzo; Lisa Eidenschink Brodersen; Robert B Gerbing; Kelly D Getz; Y-S Vera Huang; Michael Loken; Soheil Meshinchi; Jessica A Pollard; Lillian Sung; William G Woods; E Anders Kolb; Alan S Gamis; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2021-10-01       Impact factor: 3.167

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.